

	Certificate of Mailing
Date of Deposit <u>October 11, 2001</u>	Label Number: <u>EL 834597981 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this corres "Express Mail Post Office to Addressee" with suffic PATENT APPLICATION, Assistant Commissioner for	pondence is being deposited with the United States Postal Service as cient postage on the date indicated above and is addressed to: BOX Patents, Washington, D.C. 20231.
Guy Beardsley	Signature of person mailing correspondence
Printed name of person mailing correspondence	

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. § 1.53(b)			
Attorney Docket Number	50082/015002		
Applicant	Grant McFadden and Karim Essani		
Title	NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION		
PRIORITY INFORMATION:			
This application claims the benefit of the filing date of United States provisional patent application 60/239,354, filed October 11, 2000.			
SMALL ENTITY STATUS:			
☑ Applicant claims small entity sta	tus under 37 C.F.R. § 1.27.		
APPLICATION ELEMENTS:			
Cover sheet		[1] pages	
Specification		[52] pages	
Claims		[10] pages	
Abstract		[1] pages	
Drawing (Figs. 1-9)		[9] sheets	
Combined Declaration and POA, N ☐ Unsigned; ☐ Newly signed for this application ☐ A copy from prior application [** the entire disclosure of the prior a being part of the disclosure of this hereby incorporated by reference	n; SERIAL NUMBER**] and pplication is considered as new application and is	[2] pages	
Sequence Statement		[2] pages	
Sequence Listing on Paper		[6] pages	
Sequence Listing on Diskette		[1] disk	
Preliminary Amendment		[**] pages	
IDS		[**] pages	

Form PTO 1449	[**] pages
Cited References	[**] references
Recordation Form Cover Sheet and Assignment	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$370	\$370.00
Excess Claims Fee: 78 - 20 = 58 x \$9	\$522.00
Excess Independent Claims Fee: 22 - 3 = 19 x \$42	\$798.00
Multiple Dependent Claims Fee: \$140	\$140.00
Total Fees:	\$1,830.00

- ☑ Enclosed is a check for \$1,830.00 to cover the total fees.
- □ Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees.
- ☐ The filing fee is not being paid at this time.
- ☑ Please apply any other charges, or any credits, to Deposit Account No. 03-2095.

CORRESPONDENCE ADDRESS:

Kristina Bieker-Brady, Ph.D.

Reg. No. 39,109 Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Abg U, 2001

CUSTOMER NO: 21559

Signature

Date

F:\50082\50082.015002 Utility Transmittal.wpd

21559
PATENT TRADEMARK OFFICE

PATENT ATTORNEY DOCKET NO. 50082/015002

Certificate of Mailing: Date of Deposit: October 11, 2001			
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.			
Guy Beardsley Printed name of person mailing correspondence Signature of person mailing correspondence			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Grant McFadden et al.

Art Unit:

Not Assigned Yet

Serial No.:

Not Assigned Yet

Examiner:

Not Assigned Yet

Filed:

October 11, 2001

Customer No.:

21559

Title:

NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR

IMMUNE MODULATION

Assistant Commissioner For Patents Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of six pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney.

Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout

the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Krisma Bieker-Brady, Ph.D

Reg. No. 39,109

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

21559

F:\50082\50082.015002 Sequence Statement.wpd